Globus Medical (GMED) Expected to Announce Quarterly Earnings on Thursday

Globus Medical (NYSE:GMED) is expected to be issuing its Q1 2025 quarterly earnings data after the market closes on Thursday, May 8th. Analysts expect Globus Medical to post earnings of $0.74 per share and revenue of $629.74 million for the quarter.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Thursday, February 20th. The medical device company reported $0.84 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.10. The company had revenue of $657.29 million for the quarter, compared to analyst estimates of $646.19 million. Globus Medical had a return on equity of 10.83% and a net margin of 4.09%. On average, analysts expect Globus Medical to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Globus Medical Price Performance

Globus Medical stock opened at $70.49 on Tuesday. Globus Medical has a 1-year low of $50.00 and a 1-year high of $94.93. The company’s 50-day moving average is $73.14 and its 200 day moving average is $80.11. The firm has a market capitalization of $9.70 billion, a P/E ratio of 93.99, a price-to-earnings-growth ratio of 1.61 and a beta of 1.32.

Wall Street Analysts Forecast Growth

GMED has been the topic of a number of recent analyst reports. Bank of America upgraded Globus Medical from an “underperform” rating to a “neutral” rating and increased their target price for the stock from $80.00 to $97.00 in a research note on Thursday, January 9th. Needham & Company LLC reiterated a “hold” rating on shares of Globus Medical in a report on Tuesday, March 18th. Truist Financial lowered their price objective on shares of Globus Medical from $82.00 to $80.00 and set a “hold” rating for the company in a research note on Friday, April 11th. Stifel Nicolaus boosted their price target on shares of Globus Medical from $92.00 to $94.00 and gave the company a “buy” rating in a report on Friday, February 21st. Finally, Wells Fargo & Company lowered their target price on Globus Medical from $95.00 to $93.00 and set an “overweight” rating for the company in a report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $96.91.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.